InMed Pharmaceuticals Inc (INM)

Currency in USD
2.340
+0.090(+4.00%)
Closed·
2.280-0.060(-2.56%)
·
INM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
INM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2702.399
52 wk Range
1.72015.696
Key Statistics
Prev. Close
2.25
Open
2.27
Day's Range
2.27-2.399
52 wk Range
1.72-15.696
Volume
96.71K
Average Volume (3m)
3.1M
1-Year Change
-20.1%
Book Value / Share
5.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

InMed Pharmaceuticals Inc Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Compare INM to Peers and Sector

Metrics to compare
INM
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.0x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
0.4x0.9x2.6x
Price / LTM Sales
0.6x1.6x3.3x
Upside (Analyst Target)
-69.2%40.3%
Fair Value Upside
Unlock−4.4%4.7%Unlock

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-1.94 / --
Revenue / Forecast
1.26M / --
EPS Revisions
Last 90 days

INM Income Statement

People Also Watch

60.45
BMNR
-1.91%
26.6900
NKTR
+3.77%
2.45
INMB
-4.30%
2.000
VOR
-0.99%
6.1700
CYN
-4.49%

FAQ

What Stock Exchange Does InMed Pharmaceuticals Trade On?

InMed Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for InMed Pharmaceuticals?

The stock symbol for InMed Pharmaceuticals is "INM."

What Is the InMed Pharmaceuticals Market Cap?

As of today, InMed Pharmaceuticals market cap is 2.72M.

What Is InMed Pharmaceuticals's Earnings Per Share (TTM)?

The InMed Pharmaceuticals EPS (TTM) is -11.50.

From a Technical Analysis Perspective, Is INM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InMed Pharmaceuticals Stock Split?

InMed Pharmaceuticals has split 3 times.

How Many Employees Does InMed Pharmaceuticals Have?

InMed Pharmaceuticals has 13 employees.

What is the current trading status of InMed Pharmaceuticals (INM)?

As of 14 Aug 2025, InMed Pharmaceuticals (INM) is trading at a price of 2.34, with a previous close of 2.25. The stock has fluctuated within a day range of 2.27 to 2.40, while its 52-week range spans from 1.72 to 15.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.